Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies
- Registration Number
- NCT06448793
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
Physicians
- Resident of the US, Germany, or Japan
- Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
- Treated at least three new patients with resectable NSCLC in the past year
Exclusion Criteria
Patients
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Not willing to be audio-recorded during the interview
Physicians
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Not willing to be audio-recorded during the interview
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC) Approved Non-small Cell Lung Cancer (NSCLC) therapies - Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients Approved Non-small Cell Lung Cancer (NSCLC) therapies -
- Primary Outcome Measures
Name Time Method Patient sociodemographic Day 1 Responses to qualitative interview questions Day 1 Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.
Patient clinical characteristics Day 1
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Evidera
🇬🇧London, United Kingdom